| Drug General Information |
| Drug ID |
D0X1RQ
|
| Former ID |
DNCL001790
|
| Drug Name |
MTR105
|
| Drug Type |
Small molecular drug
|
| Indication |
Hypotension [ICD9: 458, 796.3; ICD10:I95]
|
Phase 2 |
[1]
|
|---|
| Company |
Meditor Pharmaceuticals
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C7H19N2O4PS
|
| Canonical SMILES |
CCOP(=O)(O)OCC.CCSC(=N)N
|
| InChI |
1S/C4H11O4P.C3H8N2S/c1-3-7-9(5,6)8-4-2;1-2-6-3(4)5/h3-4H2,1-2H3,(H,5,6);2H2,1H3,(H3,4,5)
|
| InChIKey |
CSYSULGPHGCBQD-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
9369798, 14750091, 30415300, 50008698, 51922248, 57399610, 103818814, 113447251, 117627854, 135188196, 162815846
|
| Target and Pathway |
| Target(s) |
Nitric-oxide synthase, endothelial |
Target Info |
Inhibitor |
[2]
|
|---|
|
BioCyc Pathway
|
Citrulline-nitric oxide cycle
|
|
KEGG Pathway
|
Arginine and proline metabolism
|
|
Metabolic pathways
|
|
Calcium signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
HIF-1 signaling pathway
|
|
Sphingolipid signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
VEGF signaling pathway
|
|
Platelet activation
|
|
Estrogen signaling pathway
|
|
Oxytocin signaling pathway
|
|
NetPath Pathway
|
Wnt Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
Endothelin signaling pathway
|
|
Interleukin signaling pathway
|
|
PI3 kinase pathway
|
|
VEGF signaling pathway
|
|
Pathway Interaction Database
|
Plasma membrane estrogen receptor signaling
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
Thromboxane A2 receptor signaling
|
|
SHP2 signaling
|
|
VEGFR1 specific signals
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
PAR1-mediated thrombin signaling events
|
|
Reactome
|
ROS production in response to bacteria
|
|
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
|
|
eNOS activation
|
|
Nitric oxide stimulates guanylate cyclase
|
|
VEGFR2 mediated vascular permeability
|
|
WikiPathways
|
ACE Inhibitor Pathway
|
|
EGF/EGFR Signaling Pathway
|
|
Myometrial Relaxation and Contraction Pathways
|
|
JAK/STAT
|
|
Corticotropin-releasing hormone
|
|
AGE/RAGE pathway
|
|
Endothelin Pathways
|
|
Leptin signaling pathway
|
|
Effects of Nitric Oxide
|
|
Metabolism of nitric oxide
|
|
Angiogenesis
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00482287) Pharmacokinetics and Pharmacodynamics of MTR105 in Hypotensive Cardiac Surgery Patients. U.S. National Institutes of Health. |
|---|
| REF 2 | Nitric oxide synthase inhibitor (MTR-105) during open-heart surgery. A pilot double-blind placebo-controlled study of hemodynamic effects and safety. Cardiology. 2008;111(3):181-7. |
|---|
